This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Look at Novartis' Cosentyx in treating Hidradenitis Suppurativa and how it can compete with Humira

Ticker(s): NVS, ABBV, ANAB

Who's the expert?

Dermatologist with extensive knowledge of hidradenitis suppurativa treatment methods.

Interview Goal
Discussing the the standard of care and the competitive landscape between ABBV Humira and NVS Cosentyx, as well as the clinical studies of treatments such as ANAB imsidolimab.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.